Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit

Figure 4. The study with an excluded rate ratio had no events in either group. APRICOT-2 = Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2; ASPECT-2 = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2; ATACS = Antithrombotic Therapy in Acute Coronary Syndromes; OASIS = Organization to Assess Strategies for Ischemic Syndromes; WARIS II = Warfarin, Aspirin, Reinfarction Study.
Figure 4. The study with an excluded rate ratio had no events in either group. APRICOT-2 = Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2; ASPECT-2 = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2; ATACS = Antithrombotic Therapy in Acute Coronary Syndromes; OASIS = Organization to Assess Strategies for Ischemic Syndromes; WARIS II = Warfarin, Aspirin, Reinfarction Study. Forest plot showing rate ratios of major bleeding for warfarin plus aspirin compared with aspirin alone.

This Article

  1. Ann Intern Med August 16, 2005 vol. 143 no. 4 241-250
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. December 15, 2009, 151 (12)
  1. Alert me to current issues